Delaware Healthcare’s attractive, ordinary, and unappealing features continue to offset each other, and it remains a middling source of exposure to its target sector.
Delaware Healthcare A DLHAX
- NAV / 1-Day Return 29.17 / −1.15 %
- Total Assets 834.5 Mil
-
Adj. Expense Ratio
1.210%
- Expense Ratio 1.210%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.46%
- Turnover 5%
USD | NAV as of Sep 25, 2024 | 1-Day Return as of Sep 25, 2024, 10:18 PM GMT+0
Morningstar’s Analysis DLHAX
Will DLHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.29 | 84.4 Mil | Healthcare |
Amgen Inc | 6.48 | 53.2 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 6.18 | 50.7 Mil | Healthcare |
UnitedHealth Group Inc | 5.34 | 43.8 Mil | Healthcare |
Merck & Co Inc | 4.55 | 37.3 Mil | Healthcare |
Pfizer Inc | 4.26 | 35.0 Mil | Healthcare |
Elevance Health Inc | 4.08 | 33.5 Mil | Healthcare |
Boston Scientific Corp | 3.42 | 28.1 Mil | Healthcare |
Roche Holding AG | 3.16 | 25.9 Mil | Healthcare |
Chugai Pharmaceutical Co Ltd | 3.08 | 25.3 Mil | Healthcare |
United States